top of page
Treating Cancer With Precision
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Aug 29, 2023
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR,...
Aug 24, 2023
Alpha Tau Medical to Participate in September Investor Conferences
JERUSALEM, August 24, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Aug 21, 2023
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha
- 81 lesions treated across four feasibility trials of head and neck or skin cancers demonstrated 89% complete response rate. - Two-year...
Aug 2, 2023
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023
JERUSALEM, August 02, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
bottom of page